Javascript must be enabled to continue!
Biomarkers and prevalence of cardiometabolic syndrome among people living with HIV/AIDS, Addis Ababa, Ethiopia: a hospital-based, observational study.
View through CrossRef
Abstract
Background
Although marked improvements in life expectancy have been observed with the rapid expansion of Antiretroviral Therapy (ART), Cardiometabolic Syndrome (CMetS) is becoming a serious challenge for People Living with HIV/AIDS (PLWHA). The present study aimed in determining biomarkers and prevalence of CMetS in PLWHA.
Methods
A hospital-based, observational study was carried out between January 2019 & February 2020 among HIV infected adults (n = 288). Binary logistic regression was used to estimate odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between the outcomes against the predictor variables.
Results
The current study revealed that the prevalence of CMetS was 28.5% (82/288) using the National Cholesterol Education Program (NCEP)-2005 definition; and it was 43.5% (126/288) using the International Diabetes Federation (IDF)-2005. Male gender was less likely to be associated with CMetS (OR = .086, C.I. 0.025–0.292, p < 0.001) using the NCEP-2005 definition. Individuals with longer duration on ART have an increased odds of CMetS using both the NCEP-2005 (OR = 1.024, C.I. 1.005–1.043, p = 0.014) and the IDF-2005 (OR = 1.251, C.I. 1.061–1.472, p = 0.007) definitions. The age at which ART initiated yet have an impact on the outcomes of CMetS (NCEP-2005: OR = 1.27, C.I. 1.031–1.564, p = 0.025), indicating that individuals who started ART treatment at older age are more likely to have CMetS than their younger counterparts. The study further verified that, individuals with increased waist-grid (central adiposity) were more likely to have CMetS using both the NCEP-2005 (OR = 1.21, C.I. 1.029–1.418, p = 0.021) and the IDF-2005 (OR = 1.730 C.I. 1.454–2.058, p < 0.001) definitions. PLWHA with increased in DBP (OR = 1.164, C.I.1.080–1.254, p < 0.001), Triglyceride (OR = 1.027, C.I. 0.015–0.039, p < 0.001), and low density lipoproteins (OR = 1.075, C.I. 0.020–0.134, p = 0.007) were more likely to have CMetS using the NCEP-2005 definition. PLWHA without comorbidity were less likely to have CMetS (NCEP-2005: OR = 0.086, C.I. 0.025–0.292, p < 0.001).
Conclusions
The prevalence of CMetS in the study area was high. Risk factors associated with CMetS were waist circumference, gender, duration on ART; ART initiated age, waist-grid, and comorbidity. Biomarkers that were more likely contributed to the prevalence of CMetS include triglyceride, low density lipoproteins, and systolic blood pressure.
Research Square Platform LLC
Title: Biomarkers and prevalence of cardiometabolic syndrome among people living with HIV/AIDS, Addis Ababa, Ethiopia: a hospital-based, observational study.
Description:
Abstract
Background
Although marked improvements in life expectancy have been observed with the rapid expansion of Antiretroviral Therapy (ART), Cardiometabolic Syndrome (CMetS) is becoming a serious challenge for People Living with HIV/AIDS (PLWHA).
The present study aimed in determining biomarkers and prevalence of CMetS in PLWHA.
Methods
A hospital-based, observational study was carried out between January 2019 & February 2020 among HIV infected adults (n = 288).
Binary logistic regression was used to estimate odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between the outcomes against the predictor variables.
Results
The current study revealed that the prevalence of CMetS was 28.
5% (82/288) using the National Cholesterol Education Program (NCEP)-2005 definition; and it was 43.
5% (126/288) using the International Diabetes Federation (IDF)-2005.
Male gender was less likely to be associated with CMetS (OR = .
086, C.
I.
0.
025–0.
292, p < 0.
001) using the NCEP-2005 definition.
Individuals with longer duration on ART have an increased odds of CMetS using both the NCEP-2005 (OR = 1.
024, C.
I.
1.
005–1.
043, p = 0.
014) and the IDF-2005 (OR = 1.
251, C.
I.
1.
061–1.
472, p = 0.
007) definitions.
The age at which ART initiated yet have an impact on the outcomes of CMetS (NCEP-2005: OR = 1.
27, C.
I.
1.
031–1.
564, p = 0.
025), indicating that individuals who started ART treatment at older age are more likely to have CMetS than their younger counterparts.
The study further verified that, individuals with increased waist-grid (central adiposity) were more likely to have CMetS using both the NCEP-2005 (OR = 1.
21, C.
I.
1.
029–1.
418, p = 0.
021) and the IDF-2005 (OR = 1.
730 C.
I.
1.
454–2.
058, p < 0.
001) definitions.
PLWHA with increased in DBP (OR = 1.
164, C.
I.
1.
080–1.
254, p < 0.
001), Triglyceride (OR = 1.
027, C.
I.
0.
015–0.
039, p < 0.
001), and low density lipoproteins (OR = 1.
075, C.
I.
0.
020–0.
134, p = 0.
007) were more likely to have CMetS using the NCEP-2005 definition.
PLWHA without comorbidity were less likely to have CMetS (NCEP-2005: OR = 0.
086, C.
I.
0.
025–0.
292, p < 0.
001).
Conclusions
The prevalence of CMetS in the study area was high.
Risk factors associated with CMetS were waist circumference, gender, duration on ART; ART initiated age, waist-grid, and comorbidity.
Biomarkers that were more likely contributed to the prevalence of CMetS include triglyceride, low density lipoproteins, and systolic blood pressure.
Related Results
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
Stigma Kills
Stigma Kills
Stigma due to an HIV diagnosis is a well-known phenomenon and is a major barrier to accessing care.1Over the last forty years, HIV has been transformed from a fatal disease to a ma...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Scenario of HIV infection in Pakistan
Scenario of HIV infection in Pakistan
Human immunodeficiency virus (HIV) infection, which was previously lethal, has evolved into a chronic disease that may be treated and well-managed. HIV levels in the bloodstream ma...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study
HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study
Introduction
HIV co-infection with hepatitis B (HIV-HBV) and hepatitis C (HIV-HCV) is known to affect treatment outcomes of antiretroviral therapy (ART); however, its magnitude is ...
The Burden of HIV/AIDS in Ethiopia from 1990 to 2016: Evidence from the Global Burden of Diseases 2016 Study
The Burden of HIV/AIDS in Ethiopia from 1990 to 2016: Evidence from the Global Burden of Diseases 2016 Study
BACKGROUND: The burden of HIV/AIDS in Ethiopia has not been comprehensively assessed over the last two decades. In this study, we used the 2016 Global Burden of Diseases, Injuries ...

